Skip to content
Catalyst

PapersPMID:32232984

Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants.

The Cochrane database of systematic reviews2020The record ↗

findings
2
compound
1
endpoints
2
  1. Finding, very limited evidencelowersHospital length of stay
  2. Finding, very limited evidencelowersLate-onset sepsis incidence (neonatal)
Study, every finding
meta-analysis
  • “Meta-analysis of data from twelve randomized controlled trials showed that lactoferrin supplementation to enteral feeds decreased late-onset sepsis (typical RR 0.82, 95% CI 0.74 to 0.91; typical RD -0.04, 95% CI, -0.06, -0.02; NNTB 25, 95% CI 17 to 50; 12 studies, 5425 participants, low-certainty evidence) and decreased length of hospital stay (MD -2.38, 95% CI, -4.67, -0.09; 3 studies, 1079 participants, low-certainty evidence).”
    • Participants
      1,079
      Effect
      −2.38 mean difference, 95% CI −4.67 to −0.09
      Population
      preterm neonates in hospital, lactoferrin added to enteral feeds; length of stay to discharge (3 trials pooled)
    • Participants
      5,425
      Effect
      0.82 risk ratio, 95% CI 0.74 to 0.91
      Population
      preterm neonates in randomised and quasi-randomised trials of lactoferrin added to enteral feeds (12 trials pooled)

Study record

Design
meta-analysis
Species
human / none
Population
Preterm neonates in randomized controlled trials of enteral lactoferrin supplementation, alone or with probiotics (Cochrane review); lactoferrin source not stated in abstract; abstract only
Participants
not reported
Comparator
not stated in the paper / placebo
Duration
not reported
Endpoints measured
21